UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,994,159 B2
APPLICATION NO. : 10/797903
DATED : August 9, 2011
INVENTOR(S) : Yuji Yamamoto et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 18, line 1 (Claim 1), please delete "cKit" and insert -- c-Kit --, therefor;

Column 18, line 6 (Claim 1), please delete "quinolinecarboxamide," and
insert -- quinolinecarboxamide; --, therefor;

Column 18, lines 14-15 (Claim 2), please delete "gastorintestinal" and insert -- gastrointestinal --, therefor;

Column 18, lines 16-54 (Claim 3), please **delete** claim 3.

Column 18, line 62 (Claim 4), please delete "cKit" and insert -- c-Kit --, therefor;

Column 18-19, lines 55-67 and lines 1-5 please **delete** "4. A method of inhibiting c-kit activity in a cancer cell in a patient comprising:
a) determining if a cell expresses c-Kit kinase or a mutant c-Kit kinase; and
b) if the cell is determined to express c-Kit kinase or a mutant c-Kit kinase, applying to the cell
a pharmacologically effective dose to inhibit c-Kit activity of said cKit kinase or mutant c-Kit kinase of a compound selected from the group consisting of:
4-(3-chloro-4- (cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide;
4-(3-chloro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxarnide,
N6- methoxy-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; and
N6-methoxy-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide, or a pharmaceutically acceptable salt thereof."
and **insert** -- 4. A method of inhibiting c-kit activity in a cancer cell in a patient comprising:
a) determining if a cell expresses c-Kit kinase or a mutant c-Kit kinase; and
b) if the cell is determined to express c-Kit kinase or a mutant c-Kit kinase, applying to the cell

Signed and Sealed this
Thirteenth Day of March, 2012

David J. Kappos

David J. Kappos
Director of the United States Patent and Trademark Office

a pharmacologically effective dose to inhibit c-Kit activity of said c-Kit kinase or mutant c-Kit kinase of a compound selected from the group consisting of:
4-(3-chloro-4- (cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide;
4-(3-chloro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide;
N6- methoxy-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; and
N6-methoxy-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide, or a pharmaceutically acceptable salt thereof. --, therefor.

Column 19, line 10 (Claim 6), please delete "compound)" and insert -- compound --, therefor.